Tirzepatide vs Semaglutide: What the Head-to-Head Data Actually Shows
The first direct comparison trial is in. The numbers favor tirzepatide on weight loss — but the story is more nuanced than the headlines.
Two GLP-1 injection pens side by side on a clinic countertop.
For three years, patients and physicians have asked the same question: which GLP-1 works better? Until this spring, the answer was a shrug and a meta-analysis. Now there is a head-to-head trial.
The numbers
SURMOUNT-5 randomized 751 adults with obesity to maximum-tolerated doses of tirzepatide or semaglutide for 72 weeks. Mean weight loss was 20.2% on tirzepatide versus 13.7% on semaglutide.
What the gap means in practice
A 6.5 percentage-point difference is large for an obesity trial. It is not, however, decisive for every patient. Tolerability differed: gastrointestinal side effects were modestly more common on tirzepatide, and a meaningful subset of patients reached target weight loss on semaglutide alone.
Choice of agent is increasingly about side-effect profile and insurance coverage, not pharmacology alone.
What was not measured
The trial reported weight, not cardiovascular outcomes. SELECT established CV benefit for semaglutide. The equivalent trial for tirzepatide reads out in 2027. Until then, the choice between the two agents for high-CV-risk patients is informed but not settled.
What to ask your physician
- Which agent does your plan cover at the lowest tier?
- Have you tolerated GLP-1s before?
- Is cardiovascular risk part of your prescribing rationale?
The era of one-drug-fits-all GLP-1 prescribing is ending.
